{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:30Z","timestamp":1793830470853,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.radonc.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:26:56Z","timestamp":1610623616000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4014-0297","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Cousin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Desir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ben Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Mievis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Coucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Hustinx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.01.001_b0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1148\/73.2.175","article-title":"Potentiation of X-ray effects by actinomycin D","volume":"73","author":"D\u2019angio","year":"1959","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2021.01.001_b0010","article-title":"Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer","volume":"5","author":"Graziani","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2021.01.001_b0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00256-014-1996-1","article-title":"Gemcitabine-induced radiation recall myositis","volume":"44","author":"Delavan","year":"2015","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.radonc.2021.01.001_b0020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0360-3016(02)02773-6","article-title":"Gemcitabine-induced radiation recall","volume":"53","author":"Jeter","year":"2002","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1748-717X-6-24","article-title":"Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer","volume":"6","author":"Ding","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0030","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdx115","article-title":"Nivolumab induced radiation recall pneumonitis after two years of radiotherapy","volume":"28","author":"Shibaki","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ajco.12447","article-title":"Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: case report and literature review: post radiation erlotinib induced pneumonitis","volume":"12","author":"Awad","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0040","doi-asserted-by":"crossref","unstructured":"McGovern K, Ghaly M, Esposito M, Barnaby K, Seetharamu N. Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review. Future Sci OA. 2019;5:FSO378.","DOI":"10.2144\/fsoa-2018-0123"},{"key":"10.1016\/j.radonc.2021.01.001_b0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fonc.2020.00561","article-title":"Radiation recall pneumonitis induced by anti-PD-1 blockade: a case report and review of the literature","volume":"28","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers11030305","article-title":"Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features","volume":"11","author":"Porcu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2021.01.001_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12916-020-01718-3","article-title":"Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: mechanisms and therapeutic implications","volume":"18","author":"Teng","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.radonc.2021.01.001_b0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijrobp.2010.05.017","article-title":"Computed tomography appearance of early radiation injury to the lung: correlation with clinical and dosimetric factors","volume":"81","author":"Jenkins","year":"2011","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.lungcan.2011.05.010","article-title":"Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer","volume":"74","author":"Phernambucq","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0080","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1148\/rg.244035160","article-title":"Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis","volume":"24","author":"Choi","year":"2004","journal-title":"RadioGraphics"},{"key":"10.1016\/j.radonc.2021.01.001_b0085","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1148\/rg.313105096","article-title":"Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer","volume":"31","author":"Larici","year":"2011","journal-title":"RadioGraphics"},{"key":"10.1016\/j.radonc.2021.01.001_b0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2214\/ajr.150.4.765","article-title":"CT appearance of acute radiation-induced injury in the lung","volume":"150","author":"Ikezoe","year":"1988","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.radonc.2021.01.001_b0095","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2006.07.1337","article-title":"Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non\u2013small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)","volume":"66","author":"Wang","year":"2006","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2013.08.041","article-title":"Time evolution of regional CT density changes in normal lung after IMRT for NSCLC","volume":"109","author":"Bernchou","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","article-title":"Radiation-induced lung injury","volume":"156","author":"Hanania","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.radonc.2021.01.001_b0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.radonc.2007.10.044","article-title":"Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study","volume":"85","author":"Guckenberger","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0115","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Kadoya N, Morishita Y, Sato Y, Matsushita H, Umezawa R, et al. Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer. Ahmad A, editor. PLOS ONE. 2018;13(10):e0204734.","DOI":"10.1371\/journal.pone.0204734"},{"key":"10.1016\/j.radonc.2021.01.001_b0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2009.09.006","article-title":"Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT)","volume":"69","author":"Trovo","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.semradonc.2017.04.001","article-title":"Mechanisms of normal tissue injury from irradiation","volume":"27","author":"Citrin","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0130","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jnci\/djt212","article-title":"Role of type II pneumocyte senescence in radiation-induced lung fibrosis","volume":"105","author":"Citrin","year":"2013","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.01.001_b0135","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fimmu.2017.00506","article-title":"Immunological aspect of radiation-induced pneumonitis, current treatment strategies, and future prospects","volume":"2","author":"Kainthola","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2021.01.001_b0145","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0150","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non\u2013small-cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2017.3808","article-title":"Clinical outcomes in patients with metastatic lung cancer treated with PD-1\/PD-L1 inhibitors and thoracic radiotherapy","volume":"4","author":"Hwang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.01.001_b0165","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.01.001_b0170","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2021.01.001_b0175","article-title":"Immune checkpoint inhibitor therapy\u2013related pneumonitis: patterns and management","volume":"4","author":"Kalisz","year":"2019","journal-title":"RadioGraphics"},{"key":"10.1016\/j.radonc.2021.01.001_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1148\/radiol.2018181349","article-title":"Imaging of cancer immunotherapy: current approaches and future directions","volume":"290","author":"Nishino","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2021.01.001_b0185","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1183\/23120541.00165-2019","article-title":"Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study","volume":"6","author":"Pozzessere","year":"2020","journal-title":"ERJ Open Res"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:13:59Z","timestamp":1759122839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":37,"alternative-id":["S0167814021000013"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.01.001","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}